News


  • 24 April 2017

    Epic Sciences Announces Completion of $40 Million Series D Financing

    Epic Sciences Announces Completion of $40 Million Series D Financing

    Epic Sciences (Epic) announced today that the company has completed a $40 million Series D financing led by Hermed Capital. Altos Capital Partners, Domain Associates, Genomic Health, Pagoda Investment, Reach Tone Limited, RMI Partners, Sabby Capital and VI Ventures also participated in the financing. Epic is developing a portfolio of blood-based tests that predict drug response in cancer and recently partnered with Genomic Health to commercialize the OncotypeDx® AR-V7 Nucleus Detect™ test to leverage Genomic Health's world-class commercial channel and enterprise systems.

  • 20 April 2017

    Clearside Biomedical, Inc. Announces Completion of Patient Enrollment in Phase 1/2 Open Label Clinical Trial of CLS-TA in Diabetic Macular Edema

    Clearside Biomedical, Inc. Announces Completion of Patient Enrollment in Phase 1/2 Open Label Clinical Trial of CLS-TA in Diabetic Macular Edema

    Clearside Biomedical, Inc.  (Nasdaq:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, today announced completion of enrollment of an exploratory clinical trial (the “HULK” trial) of CLS-TA for suprachoroidal administration, its proprietary suspension formulation of the corticosteroid triamcinolone acetonide, with or without intravitreal Eylea® (aflibercept), for the treatment of diabetic macular edema (“DME”).

  • 19 April 2017

    NovaMedica launched Technology Center to develop innovative drugs

    NovaMedica launched Technology Center to develop innovative drugs

    NovaMedica, a Russian pharmaceutical company (RUSNANO portfolio company), started operation of the Technology Center designed for the development and pilot production of innovative drug products. It comprises a complex of R&D laboratories and production areas with technological capabilities which are unique for the Russian pharmaceutical industry and one of the best in Europe. Crucial tasks of the Technology Center are to develop the advanced oral medical products of different pharmacotherapeutic groups, including those to treat cardiovascular and gastroenterological diseases, central nervous system diseases, and to create painkillers drugs of the new generation.  

  • 11 April 2017

    Dr. Lorianne K. Masuoka Joins Marinus Pharmaceuticals as Chief Medical Officer

    Dr. Lorianne K. Masuoka Joins Marinus Pharmaceuticals as Chief Medical Officer

    Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that Lorianne K. Masuoka, MD has joined the Company as Chief Medical Officer.  Dr. Masuoka is a board certified neurologist with more than 20 years of experience building and expanding  high value pipelines in the biopharmaceutical industry that have resulted in drug approvals and strategic alliances.

  • 10 April 2017

    Ganaxolone IV Clinical Data Presented at Leading International Status Epilepticus Medical Conference

    Ganaxolone IV Clinical Data Presented at Leading International Status Epilepticus Medical Conference

    Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, presented Phase 1 clinical data showing the safety and tolerability of ganaxolone IV, the Company's intravenous formulation of its positive allosteric modulator of GABAA, at the 6th London-Innsbruck Colloquium on Status Epilepticus and Acute Seizures in Salzburg, Austria, April 6-8, 2017. Status epilepticus (SE) is a life-threatening medical emergency associated with high mortality and limited treatments. The biennial meeting focuses on highlighting cutting edge research and clinical practice in the field of SE with the aim to lead to improvements in the treatment and outcome of this condition.

  • 05 April 2017

    Neothetics Announces Issuance by USPTO of Eighth Patent Directed to LIPO-202 Lead Clinical Asset

    Neothetics Announces Issuance by USPTO of Eighth Patent Directed to LIPO-202 Lead Clinical Asset

    Neothetics, Inc.  (NASDAQ:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market today announced the issuance of U.S. Patent Number 9,597,531 by the United States Patent and Trademark Office (USPTO).  

  • 04 April 2017

    Syndax Pharmaceuticals Adds Biopharmaceutical Industry Leader Keith A. Katkin to Board of Directors

    Syndax Pharmaceuticals Adds Biopharmaceutical Industry Leader Keith A. Katkin to Board of Directors

    Syndax Pharmaceuticals, Inc. (“Syndax,” the “Company” or “we”) (Nasdaq:SNDX), a clinical stage biopharmaceutical company focused on developing entinostat and SNDX-6352 in multiple cancer indications, today announced the appointment of Keith A. Katkin to its Board of Directors.

  • 04 April 2017

    ReVision Optics Celebrates 1,000 Raindrop Near Vision Inlay Procedures Improving Near Vision for Individuals with Presbyopia

    ReVision Optics Celebrates 1,000 Raindrop Near Vision Inlay Procedures Improving Near Vision for Individuals with Presbyopia

    ReVision Optics, Inc., a leader in implantable presbyopia-correcting corneal inlay technology, announces that 1,000 Raindrop® Near Vision Inlay procedures have been performed since the company’s commercial launch of the product in late August 2016. The Raindrop Near Vision Inlay is a novel corneal inlay for the surgical correction of presbyopia, which is a natural part of the aging process that decreases the ability of the eye to focus on near objects.

  • 31 March 2017

    Clearside Biomedical Enters into Strategic Collaboration with EyeKor to Support Clinical Development Efforts

    Clearside Biomedical Enters into Strategic Collaboration with EyeKor to Support Clinical Development Efforts

    Clearside Biomedical Inc.  (Nasdaq:CLSD), a late-stage biopharmaceutical company developing first-in-class drug therapies to treat back-of-the-eye diseases, announced today that it has entered into a strategic collaboration with  EyeKor Inc.  to support Clearside’s ophthalmic clinical trial activities. 

  • 23 March 2017

    Neothetics Provides Business Update and Reports Fourth Quarter 2016 Financial Results

    Neothetics Provides Business Update and Reports Fourth Quarter 2016 Financial Results

    Neothetics, Inc. (NASDAQ:NEOT) today provided a business update and reported financial results for the fourth quarter 2016. “We are encouraged by our progress on our Phase 2 proof of concept trial for LIPO-202 in submental fat reduction and continue to expect top-line data in June 2017,” said Mr. Jeffrey M. Nugent, a member of Neothetics’ Operating Committee and Board of Directors.